Literature DB >> 21124007

Impaired brain creatine kinase activity in Huntington's disease.

S F Zhang1, T Hennessey, L Yang, N N Starkova, M F Beal, A A Starkov.   

Abstract

BACKGROUND: Huntington's disease (HD) is associated with impaired energy metabolism in the brain. Creatine kinase (CK) catalyzes ATP-dependent phosphorylation of creatine (Cr) into phosphocreatine (PCr), thereby serving as readily available high-capacity spatial and temporal ATP buffering.
OBJECTIVE: Substantial evidence supports a specific role of the Cr/PCr system in neurodegenerative diseases. In the brain, the Cr/PCr ATP-buffering system is established by a concerted operation of the brain-specific cytosolic enzyme BB-CK and ubiquitous mitochondrial uMt-CK. It is not yet established whether the activity of these CK isoenzymes is impaired in HD.
METHODS: We measured PCr, Cr, ATP and ADP in brain extracts of 3 mouse models of HD - R6/2 mice, N171-82Q and HdhQ(111) mice - and the activity of CK in cytosolic and mitochondrial brain fractions from the same mice.
RESULTS: The PCr was significantly increased in mouse HD brain extracts as compared to nontransgenic littermates. We also found an approximately 27% decrease in CK activity in both cytosolic and mitochondrial fractions of R6/2 and N171-82Q mice, and an approximately 25% decrease in the mitochondria from HdhQ(111) mice. Moreover, uMt-CK and BB-CK activities were approximately 63% lower in HD human brain samples as compared to nondiseased controls.
CONCLUSION: Our findings lend strong support to the role of impaired energy metabolism in HD, and point out the potential importance of impairment of the CK-catalyzed ATP-buffering system in the etiology of HD.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21124007      PMCID: PMC3214941          DOI: 10.1159/000321681

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  22 in total

1.  Recommended method for the determination of creatine kinase in blood modified by the inclusion of EDTA. The Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology (SCE).

Authors:  M Hørder; E Magid; E Pitkänen; M Härkönen; J H Strömme; L Theodorsen; W Gerhardt; J Waldenström
Journal:  Scand J Clin Lab Invest       Date:  1979-02       Impact factor: 1.713

Review 2.  Mitochondrial creatine kinase in human health and disease.

Authors:  Uwe Schlattner; Malgorzata Tokarska-Schlattner; Theo Wallimann
Journal:  Biochim Biophys Acta       Date:  2005-09-27

3.  Altered Ca2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies.

Authors:  K Steeghs; A Benders; F Oerlemans; A de Haan; A Heerschap; W Ruitenbeek; C Jost; J van Deursen; B Perryman; D Pette; M Brückwilder; J Koudijs; P Jap; J Veerkamp; B Wieringa
Journal:  Cell       Date:  1997-04-04       Impact factor: 41.582

4.  Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy.

Authors:  Ivan Tkac; Janet M Dubinsky; C Dirk Keene; Rolf Gruetter; Walter C Low
Journal:  J Neurochem       Date:  2007-01-08       Impact factor: 5.372

5.  On the mechanisms of neuroprotection by creatine and phosphocreatine.

Authors:  N Brustovetsky; T Brustovetsky; J M Dubinsky
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

Review 6.  Oxidative damage in Huntington's disease pathogenesis.

Authors:  Susan E Browne; M Flint Beal
Journal:  Antioxid Redox Signal       Date:  2006 Nov-Dec       Impact factor: 8.401

7.  Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease.

Authors:  Jinho Kim; Daniel J Amante; Jennifer P Moody; Christina K Edgerly; Olivia L Bordiuk; Karen Smith; Samantha A Matson; Wayne R Matson; Clemens R Scherzer; H Diana Rosas; Steven M Hersch; Robert J Ferrante
Journal:  Biochim Biophys Acta       Date:  2010-05-09

8.  Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit.

Authors:  Femke Streijger; Frank Oerlemans; Bart A Ellenbroek; Carolina R Jost; Bé Wieringa; Catharina E E M Van der Zee
Journal:  Behav Brain Res       Date:  2005-02-28       Impact factor: 3.332

9.  Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.

Authors:  Ruth Luthi-Carter; Sarah A Hanson; Andrew D Strand; Donald A Bergstrom; Wanjoo Chun; Nikki L Peters; Annette M Woods; Edmond Y Chan; Charles Kooperberg; Dimitri Krainc; Anne B Young; Stephen J Tapscott; James M Olson
Journal:  Hum Mol Genet       Date:  2002-08-15       Impact factor: 6.150

10.  The creatine kinase/creatine connection to Alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine deposits.

Authors:  Tanja S Bürklen; Uwe Schlattner; Ramin Homayouni; Kathleen Gough; Margaret Rak; Adriana Szeghalmi; Theo Wallimann
Journal:  J Biomed Biotechnol       Date:  2006
View more
  18 in total

Review 1.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

Review 2.  Shaping the role of mitochondria in the pathogenesis of Huntington's disease.

Authors:  Veronica Costa; Luca Scorrano
Journal:  EMBO J       Date:  2012-03-23       Impact factor: 11.598

Review 3.  Metabolism in HD: still a relevant mechanism?

Authors:  Wenzhen Duan; Mali Jiang; Jing Jin
Journal:  Mov Disord       Date:  2014-08-13       Impact factor: 10.338

4.  Quantitative Proteomic Analysis Reveals Similarities between Huntington's Disease (HD) and Huntington's Disease-Like 2 (HDL2) Human Brains.

Authors:  Tamara Ratovitski; Raghothama Chaerkady; Kai Kammers; Jacqueline C Stewart; Anialak Zavala; Olga Pletnikova; Juan C Troncoso; Dobrila D Rudnicki; Russell L Margolis; Robert N Cole; Christopher A Ross
Journal:  J Proteome Res       Date:  2016-08-03       Impact factor: 4.466

Review 5.  Behavioral and neurochemical effects of proline.

Authors:  Angela T S Wyse; Carlos Alexandre Netto
Journal:  Metab Brain Dis       Date:  2011-06-04       Impact factor: 3.584

Review 6.  Mitochondrial dysfunction in neurodegenerative diseases.

Authors:  Ashu Johri; M Flint Beal
Journal:  J Pharmacol Exp Ther       Date:  2012-06-13       Impact factor: 4.030

7.  Early alterations of brain cellular energy homeostasis in Huntington disease models.

Authors:  Fanny Mochel; Brandon Durant; Xingli Meng; James O'Callaghan; Hua Yu; Emmanuel Brouillet; Vanessa C Wheeler; Sandrine Humbert; Raphael Schiffmann; Alexandra Durr
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

Review 8.  A potential role for creatine in drug abuse?

Authors:  Kristen E D'Anci; Patricia J Allen; Robin B Kanarek
Journal:  Mol Neurobiol       Date:  2011-03-12       Impact factor: 5.590

Review 9.  PGC-1α, mitochondrial dysfunction, and Huntington's disease.

Authors:  Ashu Johri; Abhishek Chandra; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2013-04-19       Impact factor: 7.376

Review 10.  Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis.

Authors:  Sylvette Ayala-Peña
Journal:  Free Radic Biol Med       Date:  2013-04-18       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.